CD274 and head and neck squamous cell carcinoma: These therapeutic vaccines have yielded promising results in several Phase I and II clinical trials in locally advanced or recurrent and metastatic HPV + HNSCC, especially in conjunction with PD-L1/PD-1 therapy [58–60].